國立虎尾科技大學 |

Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus./
Author:	Alonso, Adrian Miguel.
Description:	1 online resource (64 pages)
Notes:	Source: Masters Abstracts International, Volume: 58-01.
Contained By:	Masters Abstracts International58-01(E).
Subject:	Microbiology. -
Online resource:	click for full text (PQDT)
ISBN:	9780438155855

Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus.
Alonso, Adrian Miguel.

Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus. - 1 online resource (64 pages)

Source: Masters Abstracts International, Volume: 58-01.

Thesis (M.S.)--Boston University, 2018.

Includes bibliographical references

Background: Group B Streptococcus (GBS) is a Gram-positive bacterium that is a common cause of infection in neonates and is the predominant pathogen causing meningitis in infants. Different vaccine formulations have been evaluated in preclinical and/or clinical settings, such as polysaccharide-based vaccines, protein-based, polysaccharide-protein conjugate vaccines, and most recently a Multiple Antigen Presenting System (MAPS) vaccine. MAPS is a vaccine that is being developed in the Malley laboratory at Boston Children's Hospital that consists of GBS polysaccharides and proteins that are combined using affinity interactions.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438155855Subjects--Topical Terms:

591510
Microbiology.
Index Terms--Genre/Form:

554714
Electronic books.

Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus.
LDR:04802ntm a2200421Ki 4500 001 919003
005 20181106103645.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780438155855
035 $a (MiAaPQ)AAI10784318
035 $a (MiAaPQ)bu:13578
035 $a AAI10784318
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Alonso, Adrian Miguel. $3 1193474
245 1 0 $a Development of a Multiple Antigen Presenting System (MAPS) Vaccine for Group B Streptococcus.
264 0 $c 2018
300 $a 1 online resource (64 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 58-01.
500 $a Advisers: Carl Franzblau; Richard Malley.
502 $a Thesis (M.S.)--Boston University, 2018.
504 $a Includes bibliographical references
520 $a Background: Group B Streptococcus (GBS) is a Gram-positive bacterium that is a common cause of infection in neonates and is the predominant pathogen causing meningitis in infants. Different vaccine formulations have been evaluated in preclinical and/or clinical settings, such as polysaccharide-based vaccines, protein-based, polysaccharide-protein conjugate vaccines, and most recently a Multiple Antigen Presenting System (MAPS) vaccine. MAPS is a vaccine that is being developed in the Malley laboratory at Boston Children's Hospital that consists of GBS polysaccharides and proteins that are combined using affinity interactions.
520 $a The overall aim of this thesis is to contribute towards the development of an effective MAPS vaccine by identifying high capsule-producing GBS isolates, optimizing conditions for polysaccharide purifications, characterizing the immune response to carrier protein derivatives, and creating MAPS complexes with GBS-specific protein carriers.
520 $a Methods: The serotypes of 61 GBS clinical isolates were identified via multiplex PCR. To determine high producing strains, the supernatant polysaccharide concentrations (SPC) for type Ia and III were measured by type 14 pneumococcal and GBS Ia ELISAs, iv respectively. In addition, type III isolates were grown in different conditions (shaking vs. static, Todd Hewitt Broth vs. Todd Hewitt Broth + 0.5% yeast extracts).
520 $a For carrier protein production, genetically conserved alpC and rib were ligated onto a pet21b C terminally tagged rhizavidin (protein made by Rhizobium etli that has a very high affinity for biotin) vector. AlpC was purified and used to immunize rabbits. To determine whether the location of the terminal rhizavidin tag affected the immunogenicity of the proteins, we compared the serum titers of C- and N-terminally tagged proteins by ELISA. Additionally, AlpC was conjugated to purified pneumococcal type I polysaccharide for the creation of MAPS complexes.
520 $a Results: We serotyped 61 clinical GBS isolates, of which 18 were type Ia and 33 were type III. The type Ia isolate 21 and type III isolate 25 produced the most polysaccharide relative to the other isolates. The majority of the isolates for type III produced more capsule under shaking conditions and when grown in THY (Todd Hewitt Broth +0.5% yeast extracts).
520 $a AlpC and rib were successfully cloned into pet21b CRhiz plasmid and purified. To determine if the position of the rhizavadin tag affected immunogenicity, AlpC-C terminus was sent for immunization onto rabbits. This protein generated similar antibody titers than a N-terminally tagged AlpC.
520 $a Discussion: The majority of isolates identified from patients were type Ia and III which corresponds to published data stating that Ia and III are amongst the most common serotypes associated with early onset disease. Production of capsule was greatest in isolate 21 for the Ias and isolate 25 for the III, which may be due to enhanced expression of the cps operon.
520 $a The data for serum titers from AlpC revealed no major difference between titers generated by the C-and N-terminally tagged proteins. This suggests that placing the rhizavadin tag at the C-terminus or N-terminus for AlpC does not affect immunogenicity.
520 $a Conclusion: This work presented in this thesis contributed to the development of an effective GBS MAPS vaccine by finding high producing strains to optimize polysaccharide purifications, and purifying AlpC and immunizing with this carrier protein.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Microbiology. $3 591510
655 7 $a Electronic books. $2 local $3 554714
690 $a 0410
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Boston University. $b Medical Sciences. $3 1185651
773 0 $t Masters Abstracts International $g 58-01(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10784318 $z click for full text (PQDT)